Abstract-The smooth muscle myosin heavy chain (SM-MHC) gene encodes a major contractile protein whose expression exclusively marks the smooth muscle cell (SMC) lineage. To better understand smooth muscle differentiation at the transcriptional level, we have initiated studies to identify those DNA sequences critical for expression of the SM-MHC gene. Here we report the identification of an SM-MHC promoter-intronic DNA fragment that directs smooth muscle-specific expression in transgenic mice. Transgenic mice harboring an SM-MHC-lacZ reporter construct containing Ϸ16 kb of the SM-MHC genomic region from Ϫ4.2 to ϩ11.6 kb (within the first intron) expressed the lacZ transgene in all smooth muscle tissue types. The inclusion of the intronic sequence was required for transgene expression, since 4.2 kb of the 5Ј-flanking region alone was not sufficient for expression. In the adult mouse, transgene expression was observed in both arterial and venous smooth muscle, in airway smooth muscle of the trachea and bronchi, and in the smooth muscle layers of all abdominal organs, including the stomach, intestine, ureters, and bladder. During development, transgene expression was first detected in airway SMCs at embryonic day 12.5 and in vascular and visceral SMC tissues by embryonic day 14.5. Of interest, expression of the SM-MHC transgene was markedly reduced or absent in some SMC tissues, including the pulmonary circulation. Moreover, the transgene exhibited a heterogeneous pattern between individual SMCs within a given tissue, suggesting the possibility of the existence of different SM-MHC gene regulatory programs between SMC subpopulations and/or of episodic rather than continuous expression of the SM-MHC gene. To our knowledge, results of these studies are the first to identify a promoter region that confers complete SMC specificity in vivo, thus providing a system with which to define SMC-specific transcriptional regulatory mechanisms and to design vectors for SMC-specific gene targeting. (Circ Res. 1998;82:908-917.)
O ur understanding of muscle differentiation has been greatly enhanced in recent years with the identification of several key cis elements and trans factors that regulate expression of muscle-specific genes. 1, 2 However, the elucidation of transcriptional pathways that govern muscle differentiation has been primarily restricted to skeletal and cardiac muscle. To date, no transcription factors have yet been identified that direct SM-specific gene expression, or SMC myogenesis. 3 Unlike skeletal and cardiac myocytes, the SMC does not undergo terminal differentiation and exhibits a high degree of phenotypic plasticity, both in culture and within the animal. 3, 4 Phenotypic plasticity is particularly striking when SMCs located in the media of normal vessels are compared with SMCs located in intimal lesions resulting from vascular injury or atherosclerotic disease. [4] [5] [6] [7] Major modifications include decreased expression of SM isoforms of contractile proteins, altered growth regulatory properties, increased matrix production, abnormal lipid metabolism, and decreased contractility. 3 The process by which SMCs undergo such changes is referred to as "phenotypic modulation." 8 Importantly, these alterations in SMC protein expression patterns cannot be viewed simply as a consequence of vascular disease; instead, they are likely to contribute to its progression.
A key to understanding SMC differentiation is to identify transcriptional mechanisms that control expression of genes that are selective or specific for differentiated SMCs and that are required for its principal differentiated function, contraction. To this end, our laboratory and others have studied the expression of the contractile proteins SM ␣-actin 9,10 and SM-MHC, [11] [12] [13] [14] [15] [16] as well as a variety of proteins implicated in control of contraction, including SM22␣, 17 ,18 h 1 -calponin, 19 h-caldesmon, 20 telokin, 21 and desmin. 22 Of these gene products, only SM-MHC expression appears to be completely restricted to SMC lineages throughout development. 23 All others show at least transient expression in non-SMC tissues. 3 As such, at present, the SM-MHC gene is unique with regard to its potential utility for identification of SMC-specific transcriptional regulatory pathways and mechanisms. To date, four SM-MHC isoforms (SMC-1A, SMC-1B, SMC-2A, and SMC-2B) have been identified, 24 -26 all of which are derived from alternative splicing of a single gene. 23, 27 Alterations in expression of SM-MHC isoforms have been extensively documented in SMCs that have undergone phenotypic modulation either when placed in culture 28, 29 or in vascular lesions of both humans and several animal models of vascular disease. 30, 31 Thus, the SM-MHC gene represents an excellent candidate gene for delineating transcriptional pathways important for both normal development and diseased states.
Transcriptional regulation of the SM-MHC gene has been analyzed extensively in cultured SMCs, and several functional cis elements have been identified. [11] [12] [13] [14] [15] [16] However, because differentiation of SMCs is known to be dependent on many local environmental cues that cannot be completely reproduced in vitro, cultured SMCs are known to be phenotypically modulated compared with their in vivo counterparts. 3, 8 As such, certain limitations may apply regarding the usefulness of cultured SMCs in defining transcriptional programs that occur during normal SMC differentiation and maturation within the animal. Using transgenic mice to identify DNA sequences critical for SM-MHC expression, we have begun to investigate the molecular mechanisms that regulate SMC-specific transcription within the animal during normal development. In the present study, we report for the first time the identification of sufficient regions of the SM-MHC gene to direct SMC-specific expression in vivo in transgenic mice.
Materials and Methods

Isolation and Cloning of the Rat SM-MHC Promoter
The SM-MHC gene contains a very short untranslated first exon (88 bp in rat) that is followed by a Ͼ20-kb first intron. 32 The cloning and sequence of the 5Ј-flanking region of the rat SM-MHC gene (nucleotides Ϫ4220 to ϩ88) have been previously reported. 11, 15 To obtain the 5Ј-flanking sequence with additional intronic DNA, we screened a rat genomic phage library (Stratagene Corp) using standard Southern blotting techniques and a 32 P-radiolabeled 45mer oligonucleotide corresponding to the conserved untranslated first exon as a probe (nucleotides ϩ14 to ϩ58). One of the positive recombinant phage clones identified contained an Ϸ16-kb insert (determined by restriction enzyme analysis and partial sequencing) that spanned the SM-MHC gene from nucleotides Ϫ4229 to Ϸϩ11 600. Identical restriction enzyme patterns between rat genomic DNA and multiple positive clones revealed that none of the clones identified had undergone rearrangement.
Construction of the Rat SM-MHC-lacZ Reporters
The pUC19-lacZ vector used in the generation of SM-MHC reporter gene constructs was kindly provided by Dr Eric Olson. 33 To facilitate removal of pBS plasmid DNA, the pUC19-lacZ vector was modified by inserting NotI restriction enzyme recognition sites at the HindIII and EcoRI sites located at the borders of the pBS vector sequence. Two SM-MHC-lacZ reporter genes were constructed for the generation of transgenic mice (Figure 1 ). One construct (p4.2-lacZ) was created by ligating an Ϸ4.3-kb BglII fragment that extended from nucleotides Ϫ4220 to ϩ88 (see Reference 15) into a unique BamHI site of the pUC19-lacZ vector, and the other construct tested (p4.2ϩintron-lacZ) was generated by subcloning an Ϸ16-kb SalI fragment that extended from nucleotides Ϫ4229 to Ϸϩ11 600 into the SalI site of the pUC19-lacZ vector. To facilitate splicing of the p4.2ϩintron-lacZ construct, a synthetic splice acceptor site was ligated into the KpnI site of the pUC19-lacZ vector before insertion of the SM-MHC DNA fragment. The location of the KpnI site, between the SalI site and the lacZ gene, allowed for the correct positioning of the splice acceptor site at the ϩ11 600 end of the SM-MHC intron. The proper construction of each SM-MHC-lacZ chimeric plasmid was verified by sequencing and restriction enzyme analyses. As an additional precaution against cloning artifacts, both transgenic constructs were tested for lacZ expression in transient transfection assays in cultured rat aortic SMCs using a method that was previously described. 15 In this assay, both constructs were determined to be positive for lacZ expression.
Generation and Analysis of Transgenic Mice
Plasmid constructs p4.2-lacZ and p4.2ϩintron-lacZ were tested for SM-MHC promoter activity in transgenic mice after removal of the pBS vector DNA through NotI digestion and subsequent agarose gel purification. Transgenic mice were generated using standard methods, 17, 34 either commercially (DNX) or within the Transgenic Core Facility at The University of Virginia, Charlottesville. Transgenic mice were either killed and analyzed during embryological development (transient transgenics) or were used to establish breeding founder lines (stable transgenics). Transgene presence was assayed by polymerase chain reaction using genomic DNA purified from Selected Abbreviations and Acronyms DAB ϭ diaminobenzidine E (with number) ϭ embryonic day MHC ϭ myosin heavy chain SM ϭ smooth muscle SMC ϭ smooth muscle cell TGF ϭ transforming growth factor Figure 1 . Diagram of SM-MHC reporter gene constructs used for generation of transgenic mice. A, An Ϸ4.3-kb BglII DNA fragment of the rat SM-MHC gene that extended from nucleotides Ϫ4220 to ϩ88 (Reference 15) was subcloned into a unique BamHI site of the previously described 33 pUC19/AUG ␤-galactosidase (B-gal) vector to generate the p4.2-lacZ construct. The 5Ј-untranslated first exon (5Ј UT) is indicated. B, An Ϸ16-kb SalI DNA fragment (nucleotides Ϫ4229 to ϩ11 600) of the rat SM-MHC gene was ligated into the unique SalI site of the pUC19/ AUG B-gal vector to generate the p4.2ϩintron-lacZ (p4.2ϩInt-lacZ) construct. Restriction enzyme modifications and the addition of a synthetic splice acceptor site (SA) to this vector are described in "Materials and Methods." For both constructs, the restriction enzyme sites used for removal of the pUC19 plasmid backbone are indicated.
either placental tissue (embryonic mice) or tail clips (adult mice) according to the method of Vernet et al. 35 Transgene expression and histological analyses were performed as described previously. 17, 33 
SM-MHC Immunohistochemistry
Various SM-containing tissues were collected from 5-and 6-weekold transgenic mice and fixed overnight in methacarn (60% methanol, 30% chloroform, and 10% glacial acetic acid). Tissues were subsequently dehydrated through a graded series of methanol. Fixed dehydrated tissues were prepared for paraffin embedding by incubation in 100% xylene. Tissue was then infiltrated by incubation through a series of xylene:paraffin (3:1, 1:1, and 1:3) solutions and two final incubations in 100% paraffin before embedding in 100% paraffin. Serial sections (6 um) were placed on uncoated slides and then dried for Ϸ45 minutes on a slide warmer set at 40°C. Sections were cleared in multiple washes of 100% xylene and rehydrated through a graded ethanol series to a final incubation in PBS. Endogenous peroxidase activity was quenched by incubating slides in methanol containing 0.3% hydrogen peroxide for 30 minutes. Slides were subsequently rehydrated in PBS and blocked in a 1:50 solution of normal goat serum made up in PBS. Sections were then incubated with the primary antibody for 1 hour and washed with three changes of PBS. Detection of primary antibody was performed using a Vectastain ABC kit according to the instructions of the manufacturer with DAB as the chromagen (Vector Laboratories).
Several different SM-MHC antibodies were tested. This included a monoclonal antibody designated 9A9 that we have previously characterized 36 and that shows reactivity with the SM-1 and SM-2 isoforms of SM-MHC but shows no reactivity with nonmuscle MHCs or other proteins. However, whereas this antibody showed some reactivity with mouse SM-MHC isoforms in Western analyses, it reacted very poorly with mouse SM-MHCs in fixed tissues. In addition, although a polyclonal SM-MHC peptide antibody provided by Nagai et al 24 showed complete specificity for SM-MHC isoforms in Western analyses of SM tissues from multiple species, this antibody showed little or no reactivity with mouse SM-MHC isoforms. To circumvent these limitations, we used a rabbit antichicken gizzard SM-MHC polyclonal antibody provided by Dr Ute Groschel-Stewart (University College London). 37 We found that this antibody exhibited strong reactivity and complete specificity for SM-1 and SM-2 MHC isoforms on the basis of Western analyses of multiple mouse tissues. Moreover, consistent with previous reports, 37 this antibody showed complete specificity for SM tissues on the basis of immunostaining of multiple adult and embryonic tissues (D. Raines and G.K. Owens, unpublished data, 1998 ). This rabbit anti-chicken gizzard SM-MHC polyclonal antibody was used at a concentration of Ϸ20 g/mL in PBS. Biotinylated goat anti-rabbit secondary antibodies were purchased from Vector Laboratories and used at a concentration of 10 g/mL in PBS. Detection was carried out as described in the Vectastain kit using DAB as the chromagenic substrate. Appropriate immunohistological controls were performed to assess specificity, including exclusion of primary antibody and use of control nonimmune rabbit serum.
Results
Expression of the SM-MHC-lacZ Reporter Gene in Transgenic Mice
We previously reported that an SM-MHC promoter DNA fragment extending from nucleotides Ϫ4220 to ϩ 88 was capable of directing high-level expression in cultured rat aortic SMCs. 15 When tested in bovine endothelial cells, L6 myoblasts, and L6 myotubes, the activity of this construct was determined to be negligible. To determine whether this same promoter DNA fragment was capable of directing SMC-specific expression in the animal, this fragment was subcloned into a pBS-lacZ reporter gene construct (p4.2-lacZ) and tested for activity in transgenic mice. Thirteen independent transient transgenic mice harboring the p4.2-lacZ transgene were generated and analyzed for lacZ expression at multiple embryological stages ranging from E13.5 to E19.5. For all transgenic mice, we were unable to detect any transgene expression. These data suggest that in contrast to activity levels observed for cultured SMCs, 15 the SM-MHC promoter fragment present within the p4.2-lacZ construct did not contain sufficient DNA required for directing SMCspecific expression in transgenic mice.
Portions of the SM-MHC First Intron Were Required for Directing SMC-Specific Expression in Transgenic Mice
It is well documented that cis elements important for gene expression can be found outside the 5Ј-flanking region, including intronic regions. Because 4.2 kb of 5Ј-flanking DNA was found to be insufficient for expression in vivo, we tested a larger construct with an added intronic sequence. We screened a rat genomic phage library and identified one recombinant clone whose insert contained 4229 bp of the 5Ј-flanking region, 88 bp of the first exon, which is the untranslated sequence, and an additional 11.5 kb of first intronic sequence (total span, Ϫ4.229 to ϩ11.6). This fragment, which was essentially identical to the p4.2-lacZ construct with respect to 5Ј-flanking sequence and the presence of the 88 bp of the 5Ј-untranslated sequence, was isolated from phage by SalI digestion and subcloned into the pUC19-lacZ vector to create the SM-MHC-reporter gene plasmid p4.2ϩintron-lacZ. This construct was initially tested in cultured SMCs, where it was found to exhibit an Ϸ2-to 3-fold increase in activity compared with p4.2-lacZ.
The reporter gene p4.2ϩintron-lacZ was used to generate four independent transgenic mice: one mouse was killed at E13.5 for transgene expression analysis, and the other three were established as stable transgenic founder lines (designated as 2282, 2642, and 2820) that were used for analysis of transgene expression throughout embryological development and early adulthood. Analysis of adult mice generated from the three stable founder lines showed that lacZ transgene expression was essentially identical between the three founders and completely restricted to SM (Figure 2 ). Gross examination of the heart and lung region excised from a 5-week-old p4.2ϩintron-lacZ mouse and assayed for lacZ expression revealed that transgene expression was present in the descending thoracic aorta, coronary arteries, trachea, and bronchi ( Figure 2A ). Transgene expression was not detected in any non-SM tissues in this region, such as heart muscle and lung tissue. Of note, transgene expression was also not detected in SM-containing tissues in this region, including the esophagus, or in any of the blood vessels located within the lungs. Transgene expression was readily detectable in the major branches of the coronary arterial tree, including the left and right coronary arteries ( Figure 2B ), as well as in small coronary arteries and arterioles ( Figure 2D ) of 5-to 6-weekold transgenic mice. However, no lacZ expression could be detected in any of the coronary veins ( Figures 2B, 2D , and 3C). Transgene expression was also readily detected in the descending thoracic aorta and intercostal arteries ( Figure 2C ) as well as throughout blood vessels in the extremities and main body trunk, including many small arteries, arterioles, and veins, such as the mesentery vessels ( Figure 2E ). In contrast, expression was absent in SMCs within all pulmonary vessels, and little expression was seen in the most proximal regions of the cardiac outflow tracts. Expression of the lacZ transgene was also readily detectable in the visceral SM of the intestine (Figure 2F ), the ureter and bladder ( Figure  2G ), the stomach ( Figure 2H ), and the uterus and gallbladder (not shown). Thus, these initial analyses demonstrated that the p4.2ϩintron-lacZ construct contained sufficient DNA for expression in all SMC tissue types, although certain SMC tissues were negative at least in 5-to 6-week-old animals. Moreover, certain SM tissues, such as the aorta ( Figure 2C ), intercostal arteries ( Figure 2C ), jejunum ( Figure 2F ), and stomach ( Figure 2H ), clearly showed a mosaic pattern of transgene expression that was visible even at the gross tissue level.
To assess transgene expression at the cellular level, we performed a histological analysis of lacZ reporter expression ( Figure 3) . Results of these studies further demonstrated that transgene expression was highly restrictive to SM. For example, analysis of the bladder (data not shown) and airway SM ( Figure 3A ) demonstrated that transgene expression was highly specific and appeared to be present in virtually all SMCs located within these tissues. In contrast, SMCs within many SM tissues, including the aorta ( Figure 3B ), coronary vessels ( Figure 3C ), the intestine ( Figure 3D ), stomach (not shown), and many smaller blood vessels, including small arteries, arterioles, veins, and venules ( Figure 3E and 3F) , displayed a heterogeneous pattern of expression. Transgene expression was easily detectable in some cells but appeared to be absent in immediately adjacent cells. Results of serial sectioning showed that these observations were not due to analysis of a single sectioning plane. We also saw evidence for heterogeneity of transgene reporter expression within small vessels that lie in proximity within a given tissue. For example, Figure 3F depicts two arteries and a vein located in the parenchymal tissue surrounding the small intestine. lacZ expression is clearly visible in a portion of the vein and in one of the arteries, yet it is undetectable in the immediately adjacent artery. In contrast to these observations, analysis of SM-MHC protein expression in individual SMC by immunostaining with an SM-MHC-specific antibody showed detectable expression in all SMCs within these tissues, including the thoracic aorta and jejunum (Figure 4 ). Taken together, these results indicate that although the p4.2ϩintron-lacZ transgene exhibited SMC-specific activity and was expressed in all major SM types, it exhibited marked differences in activity in subsets of SMCs both within and between different adult SMC tissues. 
Transgene Expression in the Developing Embryo
To determine whether expression of the p4.2ϩintron-lacZ transgene resembled the developmental expression pattern of the endogenous SM-MHC gene, embryos from the three stable founder lines were obtained at various stages throughout development (E10.5 through E19.5) and analyzed for lacZ expression. Additionally, one transient founder was generated and analyzed for transgene expression at E13.5. Transgene expression patterns were essentially identical in all four independent transgenic lines (ie, one transient transgenic mouse and three stable founder lines). Expression of the SM-MHC transgene was completely restricted to SMCs, although transient expression in the atrial myocardium was observed between E12.5 and E17.5 in one of the stable lines (data not shown). However, this presumably was the result of some insertional effect, since this was not observed in the remaining three lines nor was expression of the endogenous gene detectable in the heart. 23 Transgene expression patterns of embryos derived from stable founder lines 2282, 2642, and 2820 are presented in Figures 5 and 6 . The earliest developmental stage at which transgene expression could be detected was E12.5, where lacZ expression was readily identified in the trachea and bronchi ( Figure 5A and 5B). By E14.5, transgene expression was detectable in the bronchi, intestine, stomach, trachea, and the aorta, as well as a few other vessels throughout the embryo ( Figure 5B ). Of particular interest, although transgene expression was virtually absent in the esophagus in the adult ( Figure 2H ), its expression was clearly evident in embryos ( Figure 5A through  5D ). At E16.5, transgene expression was more pronounced in the aorta than at earlier developmental time points, although it had a variegated and less intense appearance relative to other SM tissues ( Figure 5C ). Additionally, the frequency of vessels that were positive for transgene expression was higher in peripheral vessels, particularly those located in the extremities of the animal.
One of the most notable differences between the E16.5 and E19.5 embryos was a marked increase in the frequency of blood vessels that stained positive for lacZ expression ( Figures 5D and 6 ). However, lacZ expression remained undetectable in a number of vessels. Especially conspicuous was the general absence of expression in many of the large blood vessels in the head and neck region, including the internal and external carotid arteries, the jugular vein, and the cerebral arteries and veins. However, many smaller-sized blood vessels were positive for transgene expression in the head and neck region. Transgene expression was also readily detectable in many other arteries and veins throughout the body, including the iliac artery and vein ( Figure 6B ), the caudal artery and vein, the femoral artery, the umbilical arteries and vein, the ulnar and radial arteries, and the superficial arterioles and venules within the musculature of the thoracic cage ( Figure 6C ).
Although expression levels in these types of studies are certainly not quantitative, it is worth noting that levels of lacZ staining within the aorta did not appear to be as intense as staining within many other blood vessels and visceral SM tissues. In summary, results of these embryological studies support the data gathered from analysis of transgene expression in juvenile and adult mice and indicate that the p4.2ϩintron-lacZ construct contains sufficient DNA for directing SMC-specific expression in all SMC tissue types. However, results leave open the possibility that additional genomic regions may be required for SM-MHC expression in some subsets of SMCs.
Discussion The SM-MHC lacZ Transgene Was Specifically Expressed in All SMC Tissue Types
To begin to understand the mechanisms that regulate expression of the SM-MHC gene, we used transgenic mice to identify an Ϸ16-kb promoter-intronic fragment (nucleotides Ϫ4229 to Ϸϩ11 600) that was sufficient for directing SMCspecific expression in vivo. Previously, we as well as others have identified multiple cis elements contained within the first 4.2 kb of the 5Ј-flanking sequence of the SM-MHC promoter that are critical for expression in cultured SMCs. [11] [12] [13] [14] [15] [16] The fact that the p4.2-lacZ construct was found to be active in cultured SMCs, but not in the mouse, indicates that additional regulatory elements are necessary for expression within the in vivo context. The fact that the p4.2ϩintron-lacZ construct was expressed in SMC tissues within the mouse, whereas the p4.2-lacZ construct was inactive, strongly suggests that the first 11.5-kb region of intron 1 contains enhancer elements required for expression in vivo but not in cultured SMCs. Differences in requirements for expression of the SM-MHC gene in cultured SMCs versus in vivo SMCs in the mouse may be the result of the generalized phenotypic modulation of SMCs that occurs in cell culture 3 or may reflect alterations in specific local environmental cues that differ between in vivo and culture conditions. For example, the cultured SMCs used in the present studies are known to constitutively produce active TGF-␤1. 38 ,39 Moreover, we have previously shown that TGF-␤1 markedly stimulates SM-MHC expression in our cultured rat aortic SMCs and have presented evidence suggesting that this may be mediated by a conserved TGF-␤1 control element found within the 4.2-kb 5Ј promoter region. 38 Although direct evidence is lacking, it is possible that the high activity of the 4.2-kb promoter fragment in cultured SMCs may be, at least in part, TGF-␤1 dependent. There, of course, remain many other possibilities, including the presence or absence of mechanical forces in the culture system. Reusch et al 40 have shown that cyclic stretch of cultured aortic SMCs derived from neonatal rats stimulates SM-MHC expression and that such effects are dependent on specific cell-extracellular matrix interactions. In any case, much additional work will be required to define the mechanisms responsible for the differences in genomic regions required for SM-MHC expression in SMCs in vivo versus in vitro.
Heterogeneity of Transgene Expression in Vascular SMCs
There is extensive evidence for functional and structural heterogeneity of SMCs both between and within different SMC tissues. [41] [42] [43] This is not surprising given the plasticity of the SMC and the fact that it must carry out very diverse functions at different developmental stages and in response to injury or pathological stimuli. 3, 8, 44 Despite the clear evidence for heterogeneity among SMC subpopulations, the underlying mechanisms responsible for phenotypic diversity are not well understood. Results of the present studies revealed distinct patterns of transgene expression with respect to developmental stage and SMC tissue type. For example, we consistently Immunostaining of adult thoracic aorta or jejunum with a rabbit anti-chicken gizzard SM-MHC polyclonal antibody. The descending thoracic aorta and jejunum were removed from a 5-to 6-week-old transgenic mouse and fixed overnight in methacarn. The tissue was then dehydrated, embedded in paraffin, and sectioned at 6 m. A, Aortic section incubated with a rabbit anti-SM-MHC polyclonal antibody (obtained from Dr Ute Groschel-Stewart 37 ), followed by detection by incubation with a biotinylated goat anti-rabbit secondary antibody, avidin-biotin horseradish peroxidase conjugate, and DAB as the chromagenic substrate. B, Control aortic section treated as in panel A but using normal rabbit serum in place of the anti-SM-MHC primary antibody. C, Jejunal section stained as in panel A. D, Control jejunal section stained as in panel B. The SM-MHC antibody showed specific reactivity with both SM1 and SM2 isoforms of SM-MHC in Western analyses of multiple mouse, rat, and bovine tissues and cultured cells (C.P. Regan and G.K. Owens, unpublished data, 1998). Moreover, it exhibited complete SMC specificity on the basis of immunostaining of tissues derived from the mouse at multiple developmental time points.
were unable to detect transgene expression in certain blood vessels, including the pulmonary arteries and veins, at any developmental time point. In contrast, we observed in the esophagus a high level of transgene expression in the developing embryo but no detectable expression in adult mice, despite persistence of transgene expression in many other SMC tissues (eg, airways, intestine, coronary arteries, and small arterioles and veins). Finally, we observed heterogeneity in expression between adjacent individual SMCs within a given SM tissue and between blood vessels that lie in proximity. These apparent differences in transgene expression may simply reflect limitations of the methodology of detection; ie, heterogeneity may be a function of the sensitivity of the ␤-galactosidase assay rather than reflecting distinct SMC subpopulations that do or do not express the transgene. Importantly, heterogeneity of expression of SM-MHC 45 and SM ␣-actin 46 within aortic SMCs of newborn animals has been reported on the basis of immunohistochemical studies, suggesting that there may also be differences in expression of these endogenous contractile protein genes at least during early postnatal development. However, heterogeneity of lacZ transgene expression was observed in adult SM tissues in which 100% of the SMCs showed detectable SM-MHC antibody staining (eg, the aorta and jejunum; Figure 4 ). Clearly, the ability to detect SM-MHC gene expression is highly dependent on (1) whether one attempts to detect expression at the transcriptional or the translational level and (2) the sensitivity of the detection method used. Indeed, such differences in detection methodology may explain the apparent discrepancies between the developmental time course of expression of the SM-MHC transgene in the present study compared with detection of SM-MHC transcripts reported by Miano et al. 23 For example, in the present study we first detected expression of the SM-MHC transgene within the airway SMCs at E12.5 and, subsequently, in the esophageal, aortic, and gastrointestinal SMCs at E14.5. In contrast, SM-MHC transcripts were first detected by in situ hybridization in the aorta at E10.5 and only later in Figure 5 . Expression of SM-MHC 4.2ϩintron-lacZ throughout development. Embryos were harvested at various time points (E12.5 to E19.5), fixed with a 2% formaldehyde/0.2% paraformaldehyde solution, and stained overnight at room temperature for ␤-galactosidase activity using 5-bromo-chloro-3-indolyl-␤-D-galactopyranoside as the substrate. Embryos were then cleared in benzyl benzoate:benzyl alcohol (2:1). A, E12.5. B, E14.5. C, E16.5. D, E19.5. The E16.5 and E19.5 embryos were skinned and sectioned sagittally along the midline to permit dye penetration. Tr indicates trachea; Br, bronchi; Es, esophagus; St, stomach; Int, intestine; Ao, aorta; Ua, umbilical arteries; Uv, umbilical veins; Co, colon; Ula, ulnar artery; and Ra, radial artery. Embryos were harvested at E19.5, sectioned sagittally along the midline (to enhance fixation and dye penetration in these older and larger embryos), fixed with a 2% formaldehyde/0.2% paraformaldehyde solution, and stained overnight at room temperature for ␤-galactosidase activity using 5-bromo-chloro-3-indolyl-␤-D-galactopyranoside as the substrate. Embryos were then cleared in benzyl benzoate:benzyl alcohol (2:1). A, Sagittal cross section of an E19.5 embryo. B, Iliac artery and vein. C, Microvessels within the musculature of the thoracic wall. Tr indicates trachea; Br, bronchi; Es, esophagus; St, stomach; Int, intestine; Ao, aorta; RA, radial artery; and Ula, ulnar artery.
airway and visceral SMCs. 23 One must therefore be very cautious in interpreting results that involve use of very different methods with poorly defined sensitivities. Regardless of this and its potential implications, it remains to be reconciled why some SMCs in the 4.2ϩintron-lacZ mice were so strongly positive for transgene expression and others were tremendously less so, even within the same tissue.
There are a number of potential mechanisms, which are not mutually exclusive, that might explain the observed heterogeneity in SM-MHC transgene expression. First, it is possible that differences in transgene expression are the result of there being a requirement for distinct transcriptional regulatory cassettes or programs between SMC subtypes or lineages. This is analogous to a suggestion by Li et al, 17 who found that expression of a transgene consisting of the initial 445 bp of the 5Ј-flanking region of the SM22 promoter coupled to lacZ was highly restricted to arterial SMCs in the adult mouse. In contrast, no expression was observed in small arteries and arterioles or in venous or visceral SMCs. At present, there are no known SMC lineages that correlate with this restricted pattern of SM22 transgene expression. However, of interest, we observed the virtual absence of expression of the 4.2ϩin-tron-lacZ transgene in pulmonary vessels, portions of the outflow tracts of the heart, and many of the major vessels in the head and neck, all of which are believed to include a neural crest component. 47, 48 As such, it is possible that at least part of the regional heterogeneity of transgene expression observed reflects lineage-dependent differences in transcriptional control programs and that additional genomic regions are required for expression in different subsets of SMCs. A second possibility is that regional differences in SM-MHC transgene expression may reflect differences in the milieu of local environmental factors that influence SM-MHC gene expression. However, it is difficult to reconcile the "microheterogeneity" we observed between immediately adjacent SMCs within a given blood vessel or SM tissue or between microvessels that lie in proximity, either on the basis of differences in local environmental factors or on the basis of different SMC lineages, at least any that have been described to date. A third possibility that must be considered is that at least some of the microheterogeneity observed may be the result of SM-MHC gene expression being episodic; ie, expression of SM-MHC within a given SMC may not be continuous but may occur in episodic bursts that are asynchronous across different cells in a given SM tissue. An intermittent pattern of transcription may be particularly appropriate for genes, such as SM-MHC, that encode for proteins that are believed to turn over relatively slowly in vivo and that are expressed at relatively constant levels in mature SMCs. Although at present there is no direct evidence that feedback regulation of SM-MHC expression occurs in SMCs, such controls must exist given the very precise regulation of SM-MHC concentrations within the SMC. Whereas it is well established that posttranscriptional controls exist for controlling intracellular levels of cytoskeletal proteins, such as tubulin, 49 evidence of intracellular feedback controls of transcription of major cytoskeletal and contractile proteins is currently lacking. As a fourth and final explanation for the mosaic pattern of expression, it is possible that the lack of uniform expression is a penetrance problem related to the integration locus (ie, insertional variegation) as has been postulated for a number of other transgenes expressed in mice. 50 This seems unlikely, however, since (1) all four independent transgene lines we studied showed a virtually identical expression pattern, and (2) this would require some inherent difference between SMCs within a given tissue that could account for variable penetrance for a given site of transgene insertion.
The finding that the lacZ transgene was highly expressed in the esophagus during embryogenesis and was later undetectable in the adult may be the result of the rare phenomenon known as "transdifferentiation." Using multiple skeletal and SM-specific markers (including SM-MHC), Patapoutian et al 51 demonstrated that esophageal muscle tissue changes (ie, "transdifferentiates") from an SM phenotype to a skeletal muscle phenotype during the late fetal to early postnatal stage in development. The fact that this transition in phenotype was closely mimicked by the esophageal expression pattern of the SM-MHC transgene supports the transdifferentiation data and further suggests that the p4.2ϩintron-lacZ construct contained sufficient sequence for proper regulation in this tissue type. This would include any repressor elements that might be used for downregulation of transcription. Further analysis of additional developmental time points between E19.5 and the first 2 weeks after birth should allow us to determine whether transgene expression decreases in a rostrocaudal progression that was described for the transdifferentiation process. The testing of additional deleted or mutated SM-MHC-lacZ constructs may also provide further insight into the molecular regulation of this process.
The SM-MHC data in the present study add to the very recent, yet rapidly growing, list of SM-specific/selective genes whose regulatory programs are being investigated in the transgenic mouse. These genes include SM ␣-actin, 52 SM22␣, 18, 53 telokin, 21 and now SM-MHC. It will be of future interest to test whether sequence elements found to be common among these genes are functionally equivalent, especially with regard to similar and different SMC tissue types. Of particular interest is the CC(A/T) 6 GG element, or CArG-box, which binds to serum response factor and is highly conserved and present in multiple copies in each of these genes. To date, only for the SM22␣ gene has this element been specifically mutated and shown to function as a required element in vivo. 53 The identification in the present study of sufficient regions of the SM-MHC gene to drive SMC-specific expression in transgenic mice provides for the first time the appropriate context with which to begin to investigate the importance of the SM-MHC CArG elements as well as a variety of other cis elements shown to be important in regulation of this gene in cultured SMCs. [11] [12] [13] [14] [15] [16] In addition, of practical significance, the SM-MHC promoterintronic fragment that we have characterized herein represents the first genomic construct that exhibits complete SMC-restricted expression in vivo. As such, it may provide the basis for design of SMC-specific gene targeting vectors for use in experimental animal models and for gene therapy in humans.
